Adjuvants may be the key to designing vaccines with increased immunogenicity without increasing the dosage of immunogen. Cytokines, saponins, mutant enterotoxins and monophosphoryl lipids are some of the agents being developed as adjuvants for use in vaccines against cancer and infectious diseases. The findings of preclinical investigations with these molecules were presented at the IBC 2nd Annual Conference on ‘New Advances in Vaccine Technologies and Applications’ [Bethesda, US; February 1995].